488 related articles for article (PubMed ID: 29412124)
1. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
[TBL] [Abstract][Full Text] [Related]
2. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
[TBL] [Abstract][Full Text] [Related]
6. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
7. [Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
Røder ME; Storgaard H; Rungby J; Knop FK; Vilsbøll T
Ugeskr Laeger; 2016 Sep; 178(38):. PubMed ID: 27649712
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Imprialos KP; Sarafidis PA; Karagiannis AI
J Hypertens; 2015 Nov; 33(11):2185-97. PubMed ID: 26372321
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E
Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222
[TBL] [Abstract][Full Text] [Related]
11. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.
Cersosimo E; Miles JM
Curr Diabetes Rev; 2019; 15(4):314-327. PubMed ID: 30101716
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
13. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
de Germay S; Pambrun E; Pariente A; Grenet G; Bezin J; Faillie JL
Diabetes Obes Metab; 2024 May; 26(5):1678-1686. PubMed ID: 38288619
[TBL] [Abstract][Full Text] [Related]
14. The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
Bendotti G; Montefusco L; Pastore I; Lazzaroni E; Lunati ME; Fiorina P
J Endocrinol Invest; 2023 Dec; 46(12):2445-2452. PubMed ID: 37535237
[TBL] [Abstract][Full Text] [Related]
15. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
Siamashvili M; Davis SN
Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience.
Islam L; Jose D; Alkhalifah M; Blaibel D; Chandrabalan V; Pappachan JM
World J Diabetes; 2024 Mar; 15(3):463-474. PubMed ID: 38591092
[TBL] [Abstract][Full Text] [Related]
18. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Asrih M; Gariani K
Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
Papademetriou V; Geladari E
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.
La Grotta R; de Candia P; Olivieri F; Matacchione G; Giuliani A; Rippo MR; Tagliabue E; Mancino M; Rispoli F; Ferroni S; Berra CC; Ceriello A; Prattichizzo F
Cell Mol Life Sci; 2022 May; 79(5):273. PubMed ID: 35503137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
